Pirtobrutinib
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia, Lymphocytic, Chronic, B-Cell
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Lymphocytic, Small, Lymphoma, Mantle-Cell, Waldenstrom Macroglobulinemia, Ritcher's Transformation, Syndrome
Trial Timeline
— → —
NCT ID
NCT05172700About Pirtobrutinib
Pirtobrutinib is a pre-clinical stage product being developed by Eli Lilly for Leukemia, Lymphocytic, Chronic, B-Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT05172700. Target conditions include Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Lymphocytic, Small, Lymphoma, Mantle-Cell.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05172700 | Pre-clinical | Completed |
| NCT07162181 | Phase 2 | Recruiting |
| NCT06876662 | Approved | Recruiting |
| NCT06876649 | Approved | Recruiting |
| NCT06812715 | Phase 2 | Recruiting |
| NCT06588478 | Phase 2 | Recruiting |
| NCT06258174 | Phase 1 | Completed |
| NCT06190678 | Phase 1 | Completed |
| NCT06180980 | Phase 1 | Completed |
| NCT06190691 | Phase 1 | Completed |
| NCT06181006 | Phase 1 | Completed |
Competing Products
20 competing products in Leukemia, Lymphocytic, Chronic, B-Cell